39
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found

      Late Ebola virus relapse causing meningoencephalitis: a case report

      research-article
      , Dr, FRCP a , * , , FRCP f , , MRCP g , , FRCP a , , FRCP a , , PhD i , , PhD i , , FRCP a , , PhD i , , FRCR c , , FRCPath h , , MRCP a , , PhD j , , MRCP a , , FRCP b , , MRCP g , , MRCP a , , FRCA e , , MRPharmS d , , FRCPath a , , PhD i , , Prof, PhD i , , MSc k , , FRCP g , , MRCP g , , MD g , , FRCR g , , MRCP g , , FRCP g , , PhD i , , FRCPath h , , FRCPath a , , PhD i , , FRCPath j , , PhD k , , FRCP g , i
      Lancet (London, England)
      Elsevier
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Summary

          Background

          There are thousands of survivors of the 2014 Ebola outbreak in west Africa. Ebola virus can persist in survivors for months in immune-privileged sites; however, viral relapse causing life-threatening and potentially transmissible disease has not been described. We report a case of late relapse in a patient who had been treated for severe Ebola virus disease with high viral load (peak cycle threshold value 13·2).

          Methods

          A 39-year-old female nurse from Scotland, who had assisted the humanitarian effort in Sierra Leone, had received intensive supportive treatment and experimental antiviral therapies, and had been discharged with undetectable Ebola virus RNA in peripheral blood. The patient was readmitted to hospital 9 months after discharge with symptoms of acute meningitis, and was found to have Ebola virus in cerebrospinal fluid (CSF). She was treated with supportive therapy and experimental antiviral drug GS-5734 (Gilead Sciences, San Francisco, Foster City, CA, USA). We monitored Ebola virus RNA in CSF and plasma, and sequenced the viral genome using an unbiased metagenomic approach.

          Findings

          On admission, reverse transcriptase PCR identified Ebola virus RNA at a higher level in CSF (cycle threshold value 23·7) than plasma (31·3); infectious virus was only recovered from CSF. The patient developed progressive meningoencephalitis with cranial neuropathies and radiculopathy. Clinical recovery was associated with addition of high-dose corticosteroids during GS-5734 treatment. CSF Ebola virus RNA slowly declined and was undetectable following 14 days of treatment with GS-5734. Sequencing of plasma and CSF viral genome revealed only two non-coding changes compared with the original infecting virus.

          Interpretation

          Our report shows that previously unanticipated, late, severe relapses of Ebola virus can occur, in this case in the CNS. This finding fundamentally redefines what is known about the natural history of Ebola virus infection. Vigilance should be maintained in the thousands of Ebola survivors for cases of relapsed infection. The potential for these cases to initiate new transmission chains is a serious public health concern.

          Funding

          Royal Free London NHS Foundation Trust.

          Related collections

          Most cited references16

          • Record: found
          • Abstract: found
          • Article: not found

          Ebola hemorrhagic fever in Kikwit, Democratic Republic of the Congo: clinical observations in 103 patients.

          During the 1995 outbreak of Ebola hemorrhagic fever in the Democratic Republic of the Congo, a series of 103 cases (one-third of the total number of cases) had clinical symptoms and signs accurately recorded by medical workers, mainly in the setting of the urban hospital in Kikwit. Clinical diagnosis was confirmed retrospectively in cases for which serum samples were available (n = 63, 61% of the cases). The disease began unspecifically with fever, asthenia, diarrhea, headaches, myalgia, arthralgia, vomiting, and abdominal pain. Early inconsistent signs and symptoms included conjunctival injection, sore throat, and rash. Overall, bleeding signs were observed in <45% of the cases. Typically, terminally ill patients presented with obtundation, anuria, shock, tachypnea, and normothermia. Late manifestations, most frequently arthralgia and ocular diseases, occurred in convalescent patients. This series is the most extensive number of cases of Ebola hemorrhagic fever observed during an outbreak.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Successful treatment of ebola virus-infected cynomolgus macaques with monoclonal antibodies.

            Ebola virus (EBOV) is considered one of the most aggressive infectious agents and is capable of causing death in humans and nonhuman primates (NHPs) within days of exposure. Recent strategies have succeeded in preventing acquisition of infection in NHPs after treatment; however, these strategies are only successful when administered before or minutes after infection. The present work shows that a combination of three neutralizing monoclonal antibodies (mAbs) directed against the Ebola envelope glycoprotein (GP) resulted in complete survival (four of four cynomolgus macaques) with no apparent side effects when three doses were administered 3 days apart beginning at 24 hours after a lethal challenge with EBOV. The same treatment initiated 48 hours after lethal challenge with EBOV resulted in two of four cynomolgus macaques fully recovering. The survivors demonstrated an EBOV-GP-specific humoral and cell-mediated immune response. These data highlight the important role of antibodies to control EBOV replication in vivo, and support the use of mAbs against a severe filovirus infection.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Efficacy of immune plasma in treatment of Argentine haemorrhagic fever and association between treatment and a late neurological syndrome.

              In a double-blind trial patients with Argentine haemorrhagic fever treated with immune plasma within 8 days of the onset of the disease had a much lower mortality than those given normal plasma. Some patients treated with immune plasma developed late neurological complications.
                Bookmark

                Author and article information

                Contributors
                Journal
                Lancet
                Lancet
                Lancet (London, England)
                Elsevier
                0140-6736
                1474-547X
                30 July 2016
                30 July 2016
                : 388
                : 10043
                : 498-503
                Affiliations
                [a ]Department of Infection, Royal Free London NHS Foundation Trust, London, UK
                [b ]Department of Neurology, Royal Free London NHS Foundation Trust, London, UK
                [c ]Department of Radiology, Royal Free London NHS Foundation Trust, London, UK
                [d ]Department of Pharmacy, Royal Free London NHS Foundation Trust, London, UK
                [e ]Division of Surgery, University College London, London, UK
                [f ]Research Department of Infection and Population Health, University College London, London, UK
                [g ]Queen Elizabeth University Hospital, Glasgow, UK
                [h ]Regional Virus Laboratory Specialist Virology Centre, Edinburgh Royal Infirmary, Edinburgh, UK
                [i ]MRC–University of Glasgow Centre for Virus Research, Glasgow, UK
                [j ]Virus Reference Department, National Infection Service, Public Health England, Colindale, UK
                [k ]High Containment Microbiology Department, National Infection Service, Public Health England, Colindale, UK
                Author notes
                [* ]Correspondence to: Dr Michael Jacobs, Department of Infection, Royal Free London NHS Foundation Trust, London NW3 2QG, UKCorrespondence to: Dr Michael JacobsDepartment of InfectionRoyal Free London NHS Foundation TrustLondonNW3 2QGUK michael.jacobs@ 123456ucl.ac.uk
                Article
                S0140-6736(16)30386-5
                10.1016/S0140-6736(16)30386-5
                4967715
                27209148
                07286d71-cfa0-46a9-b581-c3b25d0b20c4
                © 2016 Elsevier Ltd. All rights reserved.
                History
                Categories
                Articles

                Medicine
                Medicine

                Comments

                Comment on this article